Information  X 
Enter a valid email address

Devro PLC (DVO)

  Print          Annual reports

Thursday 25 April, 2019

Devro PLC

Trading Update

RNS Number : 0134X
Devro PLC
25 April 2019
 

25 April 2019

 

Devro plc

 

Trading Update

 

Devro plc ("Devro" or the "Company"), one of the world's leading manufacturers of collagen products for the food industry, issues the following trading update for the period 1 January 2019 to the current date ("the period"), ahead of its Annual General Meeting to be held at 11.00am today.

Trading in the period was in line with the Board's expectations, with momentum building through the quarter after a slower start to the year.

We continue to see good trading in North America, South East Asia and China, offset by ongoing challenging conditions in Russia, Japan and Latin America. As previously indicated, we expect 2019 revenue growth to be H2 weighted, as it will benefit from the build in sales of Fine Ultra, as well as underlying market growth.

Our cost saving initiatives are on track and we are confident of being able to meet the previously outlined targets.

Devro remains well placed to make good progress during 2019.

Chairman Search

As announced on 15 November 2018, Gerard Hoetmer will retire as Chairman and Director of the Company at the conclusion of today's Annual General Meeting.  The search for a new Chairman is well advanced and the Board anticipates an announcement will be made in the near future. Current Senior Independent Director, Paul Withers, will serve as interim Chairman from the conclusion of today's Annual General Meeting until the new Chairman is appointed.

ENDS

 

Contacts:

 

Devro plc

Rutger Helbing

Chief Executive Officer

Tel: 020 3865 7637

Jackie Callaway

Chief Financial Officer

Tel: 020 3865 7637

 

FTI Consulting

Richard Mountain / Nick Hasell


Tel: 020 3727 1340

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TSTSEDFWLFUSEIL

a d v e r t i s e m e n t